Clinical bottom line
Air pollution is a significant contributor to the increasing prevalence and severity of allergic diseases, particularly allergic rhinitis. Exposure to pollutants such as particulate matter (PM), nitrogen dioxide (NO₂), and ozone exacerbates symptoms by promoting airway inflammation and immune dysregulation. Effective management requires both environmental control strategies and optimized pharmacotherapy tailored to pollution-related triggers. Clinicians should incorporate air quality considerations into patient education and treatment plans to improve outcomes in allergic disease management (Geng et al., 2025; Li et al., 2020).
What the evidence shows
Geng et al. (2025) performed a bibliometric analysis demonstrating a growing body of research linking air pollution with allergic rhinitis, highlighting pollutants’ role in symptom exacerbation and disease burden globally.
Li et al. (2020) review mechanistic and clinical data showing that exposure to ambient air pollutants increases nasal mucosal inflammation, heightens IgE-mediated responses, and worsens allergic rhinitis symptoms. They emphasize the importance of pollution mitigation and personalized management strategies.
Xu et al. (2026) provide a comprehensive review detailing how pollutants disrupt epithelial barriers and modulate immune responses, contributing to allergic sensitization and chronic inflammation.
Sun et al. (2026) analyze childhood allergic diseases in Chongqing, China, quantifying the relative contributions of climate factors and air pollution. Their findings underscore air pollution as a key modifiable risk factor influencing disease prevalence.
Lee et al. (2021) summarize epidemiological and experimental evidence linking air pollution with allergic rhinitis, advocating for integrated public health and clinical approaches to reduce exposure and manage symptoms.
D’Amato et al. (2008) offer foundational insights into outdoor air pollution’s impact on allergic airway disease, supporting the relevance of pollutant control in allergy prevention.
Sharma et al. (2025) extend the discussion to household air pollution, highlighting indoor air quality management as a critical component in reducing allergic disease morbidity.
Caveats and uncertainty
Variability in pollutant types, concentrations, and individual susceptibility complicates risk assessment.
Most epidemiological studies are observational, limiting causal inference.
Interactions between air pollution and other environmental or genetic factors remain incompletely understood.
Effectiveness of specific environmental interventions in diverse settings requires further validation.
Long-term impact of pollution reduction on allergic disease incidence and progression needs more robust evidence.
How this may change practice
Clinicians should routinely assess environmental exposures, including air pollution, when evaluating allergic disease patients.
Patient education should incorporate strategies to minimize exposure, such as avoiding outdoor activities during high pollution periods and improving indoor air quality.
Pharmacologic management may require adjustment during pollution peaks to control exacerbations.
Collaboration with public health initiatives targeting air pollution reduction can complement clinical care.
Emerging biomarkers of pollution-related allergic inflammation may aid in personalized treatment in the future.